{"success":true,"data":{"pressRelease":{"id":"165767","rtpr_id":"nBw5TkvW2a-20261009","ticker":"RCUS","exchange":"NYSE","all_tickers":["RCUS"],"title":"Arcus Biosciences Announces New Employment Inducement Grants","author":"Business Wire","published_at":"2026-10-09T20:35:00.089Z","article_body":"Arcus Biosciences Announces New Employment Inducement Grants\n\nArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global\nbiopharmaceutical company focused on developing differentiated molecules and\ncombination therapies for the treatment of cancer and inflammatory diseases,\ntoday announced that the Compensation Committee of the Company’s Board of\nDirectors granted 2 new employees options to purchase a total of 9,150 shares\nof the Company’s common stock at an exercise price per share of $23.83,\nwhich was the closing price on October 8, 2026, and restricted stock units to\nacquire a total of 4,600 shares of the Company’s common stock. The equity\nawards were granted pursuant to the Company’s 2020 Inducement Plan, which\nwas approved by the Company’s Board of Directors in January 2020 pursuant to\nthe “inducement exception” under NYSE Listed Company Manual Rule 303A.08.\n\nAbout Arcus Biosciences\n\nArcus Biosciences is a clinical-stage, global biopharmaceutical company\nfocused on developing differentiated molecules for the treatment of cancer and\ninflammatory diseases. In partnership with industry collaborators, patients\nand physicians around the world, Arcus is expediting the development of its\nlate-stage portfolio of first- and/or best-in-class medicines against\nwell-characterized biological targets and pathways and studying novel,\nbiology-driven combinations that have the potential to help people with cancer\nlive longer. Founded in 2015, the company has advanced multiple\ninvestigational medicines into registrational clinical trials including\ncasdatifan, a HIF-2α inhibitor for clear cell renal cell carcinoma, and\nquemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more\ninformation about Arcus Biosciences’ clinical and preclinical programs,\nplease visit www.arcusbio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.arcusbio.com&esheet=54619297&newsitemid=20261009482200&lan=en-US&anchor=www.arcusbio.com&index=1&md5=5d0e5bafe88cef043f63d25e255ceb0e)\n.\n\nInducement PR\n\nSource: Arcus Biosciences\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261009482200/en/\n(https://www.businesswire.com/news/home/20261009482200/en/)\n\nInvestor Inquiries:\nPia Eaves\nVP of Investor Relations & Strategy\n(617) 459-2006\npeaves@arcusbio.com (mailto:peaves@arcusbio.com)\n\nMedia Inquiries:\nHolli Kolkey\nVP of Corporate Affairs\n(650) 922-1269\nhkolkey@arcusbio.com (mailto:hkolkey@arcusbio.com)\n\nMaryam Bassiri\nDirector of Corporate Affairs\n(510) 406-8520\nmbassiri@arcusbio.com (mailto:mbassiri@arcusbio.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5TkvW2a-20261009","title":"Arcus Biosciences Announces New Employment Inducement Grants","author":"Business Wire","ticker":"RCUS","created":"2026-10-09T20:35:00.089Z","tickers":["RCUS"],"exchange":"NYSE","article_body":"Arcus Biosciences Announces New Employment Inducement Grants\n\nArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global\nbiopharmaceutical company focused on developing differentiated molecules and\ncombination therapies for the treatment of cancer and inflammatory diseases,\ntoday announced that the Compensation Committee of the Company’s Board of\nDirectors granted 2 new employees options to purchase a total of 9,150 shares\nof the Company’s common stock at an exercise price per share of $23.83,\nwhich was the closing price on October 8, 2026, and restricted stock units to\nacquire a total of 4,600 shares of the Company’s common stock. The equity\nawards were granted pursuant to the Company’s 2020 Inducement Plan, which\nwas approved by the Company’s Board of Directors in January 2020 pursuant to\nthe “inducement exception” under NYSE Listed Company Manual Rule 303A.08.\n\nAbout Arcus Biosciences\n\nArcus Biosciences is a clinical-stage, global biopharmaceutical company\nfocused on developing differentiated molecules for the treatment of cancer and\ninflammatory diseases. In partnership with industry collaborators, patients\nand physicians around the world, Arcus is expediting the development of its\nlate-stage portfolio of first- and/or best-in-class medicines against\nwell-characterized biological targets and pathways and studying novel,\nbiology-driven combinations that have the potential to help people with cancer\nlive longer. Founded in 2015, the company has advanced multiple\ninvestigational medicines into registrational clinical trials including\ncasdatifan, a HIF-2α inhibitor for clear cell renal cell carcinoma, and\nquemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more\ninformation about Arcus Biosciences’ clinical and preclinical programs,\nplease visit www.arcusbio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.arcusbio.com&esheet=54619297&newsitemid=20261009482200&lan=en-US&anchor=www.arcusbio.com&index=1&md5=5d0e5bafe88cef043f63d25e255ceb0e)\n.\n\nInducement PR\n\nSource: Arcus Biosciences\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261009482200/en/\n(https://www.businesswire.com/news/home/20261009482200/en/)\n\nInvestor Inquiries:\nPia Eaves\nVP of Investor Relations & Strategy\n(617) 459-2006\npeaves@arcusbio.com (mailto:peaves@arcusbio.com)\n\nMedia Inquiries:\nHolli Kolkey\nVP of Corporate Affairs\n(650) 922-1269\nhkolkey@arcusbio.com (mailto:hkolkey@arcusbio.com)\n\nMaryam Bassiri\nDirector of Corporate Affairs\n(510) 406-8520\nmbassiri@arcusbio.com (mailto:mbassiri@arcusbio.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-09T20:35:00.12757587Z","server_sent_at_ms":1791578100127},"received_at":"2026-10-09T20:35:00.180Z","source_url":"https://www.businesswire.com/news/home/20261009482200/en/"},"analysis":{"id":"154153","press_release_id":"165767","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Arcus Biosciences granted 2 new employees options to purchase 9,150 shares at $23.83 and RSUs covering 4,600 shares as employment inducement awards.\n\nThe grants were made under the company's 2020 Inducement Plan pursuant to the NYSE inducement exception and priced at the October 8, 2026 closing price.\n\nThis is a routine boilerplate equity grant disclosure with no bearing on the company's clinical pipeline or financial outlook.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grant notice -- suppress."},"keyFigures":{"customDimensions":{"rsu_shares":4600,"option_shares":9150,"exercise_price":23.83,"employees_granted":2}},"namedEntities":{"people":[],"products":["casdatifan","quemliclustat"],"companies":[{"name":"Arcus Biosciences, Inc.","ticker":"RCUS"}],"dollarAmounts":[{"amount":"$23.83","context":"option exercise price (closing price on October 8, 2026)"}]},"materialImpact":{"score":1,"reasoning":"Routine employment inducement equity grants to 2 new employees under the NYSE inducement exception. Boilerplate disclosure with no strategic or financial significance."},"tickerRelevance":{"others":[],"primary":"RCUS"},"globalImportance":5,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap-biotech","eventGravity":"routine-inducement-grant","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Arcus Biosciences granted 2 new employees options to purchase 9,150 shares at $23.83 and RSUs covering 4,600 shares as employment inducement awards.\n\nThe grants were made under the company's 2020 Inducement Plan pursuant to the NYSE inducement exception and priced at the October 8, 2026 closing price.\n\nThis is a routine boilerplate equity grant disclosure with no bearing on the company's clinical pipeline or financial outlook.","key_figures":{"customDimensions":{"rsu_shares":4600,"option_shares":9150,"exercise_price":23.83,"employees_granted":2}},"named_entities":{"people":[],"products":["casdatifan","quemliclustat"],"companies":[{"name":"Arcus Biosciences, Inc.","ticker":"RCUS"}],"dollarAmounts":[{"amount":"$23.83","context":"option exercise price (closing price on October 8, 2026)"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-09T20:35:03.313Z","global_importance":5,"audience_relevance":8,"importance_components":{"tickerTier":"small-cap-biotech","eventGravity":"routine-inducement-grant","issuerAuthored":true}},"durationMs":3143,"modelName":"glm-5.3-flashx"}}